This is a working overview of Cardarine, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-23. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
The effect of a mutation on protein sequence depends in part on where in the genome it occurs, especially whether it is in a coding or non-coding region. Mutations in the non-coding regulatory sequences of a gene, such as promoters, enhancers, and silencers, can alter levels of gene expression, but are less likely to alter the protein sequence. Mutations within introns and in regions with no known biological function (e.g. pseudogenes, retrotransposons) are generally neutral, having no effect on phenotype – though intron mutations could alter the protein product if they affect mRNA splicing. Mutations that occur in coding regions of the genome are more likely to alter the protein product, and can be categorized by their effect on amino acid sequence:
The cover of Private Eye announced "A Legend Lives" and one major newspaper ended an editorial by proclaiming that the "balance of probability" was that Heseltine would be prime minister before the end of the year – this being at a time when John Major's leadership had lost much credibility after the scandals following the "Back to Basics" campaign the previous autumn. Heseltine also acted to enforce a squeaky clean image at this time, by announcing an inquiry in July 1994, into allegations of insider dealing by Jeffrey Archer (there was insufficient evidence to prosecute), and by personally (rather than in writing) announcing an inquiry into whether a weapons manufacturing company called BMARC had broken government guidelines on trading with Iraq in the late 1980s. Heseltine launched a White Paper on Competitiveness in 1994. He was active in leading British trade delegations to South Africa, South America, India and Russia, but despite his enthusiasm for European Unity was seen to display little interest in the nuts and bolts of trade negotiations with the continent. In 1994 Heseltine planned to privatise 40% of the Post Office, a move which the Conservatives had previously shied away from. He was seen as imperious and intolerant by backbench opponents concerned at the threat to local postal services ("he seemed to have lost touch" one commented after a meeting), and the plan was abandoned by the Cabinet as unlikely to pass the House of Commons, as the Major government's majority had dropped to 14 by then.
== Signs and symptoms == People with hypothyroidism often have no or only mild symptoms. Numerous signs and symptoms are associated with hypothyroidism and can be related to the underlying cause, or a direct effect of not having enough thyroid hormones. Many symptoms of hypothyroidism are otherwise common and do not necessarily indicate thyroid problem. Hashimoto's thyroiditis may present with the mass effect of a goiter (enlarged thyroid gland). In middle-aged women, the symptoms may be mistaken for those of menopause.
Sources: en.wikipedia.org
=== Analogues === Although several related compounds are disclosed in the original patent, no activity data are provided and it was unclear whether these share tianeptine's unique pharmacological effects. More recent structure-activity relationship studies have since been conducted, providing some further insight on μ-opioid, δ-opioid, and pharmacokinetic activity. Derivatives where the aromatic chlorine substituent is replaced by bromine, iodine or methylthio, and/or the heptanoic acid tail is varied in length or replaced with other groups such as 3-methoxypropyl, show similar or increased opioid receptor activity relative to tianeptine, with up to 13x higher potency than tianeptine itself. Amineptine, the most closely related drug to have been widely studied, is a dopamine reuptake inhibitor with no significant effect on serotonin levels, nor opioid agonist activity. Tianeptinaline and tianeptinostat, analogues of tianeptine, are potent histone deacetylase (HDAC) inhibitors.
In Truth Social, Trump also claimed that Xi agreed on rebranding artificial intelligence to "super intelligence", saying "Like almost everyone else, he seemed to like calling the poorly and inaccurately named Artificial Intelligence to a far more accurate and important name, SUPER INTELLIGENCE" and that "That would be ‘SUPER!’ Everyone last night agreed, also." In response, the spokesperson of the Ministry of Foreign Affairs of China said that China respects the US's use of the term "super intelligence". Russian President Vladimir Putin commented on the visit, saying that Russia welcomes dialogue between the United States and China, and that whatever results the United States and China achieve will affect the entire world economy. After Xi left the US, President Trump called Japanese Prime Minister Sanae Takaichi. Trump explained to Takaichi the content of his talks with Xi Jinping during the meeting. The two exchanged views on China-related issues. Takaichi said that she and Trump maintained communication before and after Xi's visit, showing the close relationship between the US and Japan.
=== Organisational changes === There is some suggestion that organisational changes may reduce incidence of pressure ulcers, with healthcare professionals central to the prevention of pressure ulcers in both hospital and community settings. It is not clear from studies on the effectiveness of these approaches as to the best organisational change that would benefit those at risk of pressure ulcers including organisation of health services, risk assessment tools, wound care teams, and education. This is largely due to the lack of high-quality research in these areas.
North Korean citizens returning from other countries were subjected to a 40-day isolation period, plus a subsequent 30-day "medical observation" period. According to North Korean media, nearly 7,000 North Koreans had been subjected to these rules as of 1 March. On 14 March, North Korean state media reported that there were still no confirmed cases in its territory. Kim Jong Un ordered the construction of new hospitals in the country on 18 March. North Korean state media also reported the prior day that groundbreaking on the new Pyongyang General Hospital was underway. Kim told a newspaper linked to the ruling Workers' Party of Korea that the construction of new hospitals was being done for general improvement of the nation's healthcare system, without mentioning COVID-19. On 20 March, North Korean media reported that excepting three foreigners, more than 2,590 people had been released from quarantine in North Pyongan and South Pyongan provinces. Outside organizations provided aid to fight the virus: the Russian government provided test kits; the WHO announced plans to send supplies despite the lack of confirmed cases; and the International Federation of Red Cross and Red Crescent Societies, U.S. State Department, and South Korean government all indicated willingness to help. The U.S. government worked with the United Nations to make exceptions to sanctions, though the organizations were also criticized for slowing down the process for providing aid.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.